| scholarly article | Q13442814 |
| P2093 | author name string | van der Heijde DM | |
| van de Putte LB | |||
| van Riel PL | |||
| van Leeuwen MA | |||
| van Rijswijk MH | |||
| van 't Hof MA | |||
| Lubberts EW | |||
| Theunisse LA | |||
| P2860 | cites work | Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'. | Q41139247 |
| Clinical judgment in rheumatoid arthritis. II. Judging 'current disease activity' in clinical practice | Q41139272 | ||
| Inability of rheumatologists to describe their true policies for assessing rheumatoid arthritis. | Q41151665 | ||
| Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. | Q53021508 | ||
| Judging "current disease activity" in rheumatoid arthritis--an international comparison. | Q53433183 | ||
| Which traditional measures should be used in rheumatoid arthritis clinical trials? | Q57244960 | ||
| Preference for endpoint measures in clinical trials: results of structured workshops | Q70606506 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 916-920 | |
| P577 | publication date | 1990-11-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score | |
| P478 | volume | 49 |
| Q51733704 | A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference. |
| Q33565430 | A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis |
| Q41937008 | A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis. |
| Q50946347 | A large chronic pericardial effusion in an ultramarathon runner with anti-CCP positive rheumatoid arthritis. |
| Q95302182 | A new laboratory surrogate (Monocyte Chemotactic Protein-1) for Disease Activity Score28: a favourable indicator for remission in rheumatoid arthritis |
| Q72649391 | A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs |
| Q55080014 | A protocol for a randomised controlled trial of prefabricated versus customised foot orthoses for people with rheumatoid arthritis: the FOCOS RA trial [Foot Orthoses - Customised v Off-the-Shelf in Rheumatoid Arthritis]. |
| Q41929355 | A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a county hospital |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q53121954 | A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. |
| Q33578184 | A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis |
| Q60920131 | Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study |
| Q24817087 | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score |
| Q73832073 | Adalimumab, a fully human anti-TNF-alpha monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patients |
| Q34156535 | Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature |
| Q35907814 | Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease |
| Q87649260 | Alexithymia, mood states and pain experience in systemic lupus erythematosus and rheumatoid arthritis |
| Q40355045 | Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept |
| Q28258273 | Analysis of serum heat shock protein 70 (HSPA1A) concentrations for diagnosis and disease activity monitoring in patients with rheumatoid arthritis |
| Q35151573 | Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis |
| Q46106693 | Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis |
| Q39526831 | Antibodies against M. Bovis 65 KDa Heat Shock Protein and Its P180-188 Epitope in Sera of Patients with Juvenile Idiopathic Arthritis |
| Q43928839 | Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations |
| Q74242481 | Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? |
| Q104064428 | Assessment of a dried blood spot C-reactive protein method to identify disease flares in rheumatoid arthritis patients |
| Q48250371 | Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in Rheumatoid Arthritis. |
| Q37471597 | Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds |
| Q24812290 | Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis. |
| Q99564907 | Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis |
| Q35614010 | Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. |
| Q37140640 | Association of the polymorphisms of TRAF1 (rs10818488) and TNFAIP3 (rs2230926) with rheumatoid arthritis and systemic lupus erythematosus and their relationship to disease activity among Egyptian patients |
| Q41890125 | Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: A case-control study. |
| Q38445673 | Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records |
| Q46269700 | Autonomic impairment in rheumatoid arthritis. |
| Q80463745 | B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection |
| Q24235447 | Balance training (proprioceptive training) for patients with rheumatoid arthritis |
| Q24240247 | Balance training (proprioceptive training) for patients with rheumatoid arthritis |
| Q36234106 | Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis |
| Q26776432 | Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? |
| Q57244886 | Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: Comment on the concise communication by Boers |
| Q33565191 | Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity |
| Q43800165 | Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone |
| Q45917390 | Brief Report: to squeeze or not to squeeze, that is the question! Optimizing the disease activity score in 28 joints by adding the squeeze test of metatarsophalangeal joints in early rheumatoid arthritis. |
| Q50879100 | Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort. |
| Q41410223 | Can we predict aggressive disease? |
| Q45906917 | Caregiving appraisal and disease activity in early inflammatory arthritis. |
| Q48883146 | Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters |
| Q28483728 | Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements |
| Q45959202 | Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. |
| Q56517416 | Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol |
| Q47333469 | Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure |
| Q24674942 | Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study |
| Q54747658 | Combined measurement of multiple acute phase reactants to predict relapse of rheumatoid arthritis. |
| Q55068670 | Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. |
| Q47367147 | Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study. |
| Q35760044 | Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values |
| Q85913598 | Comparison of OMERACT-RAMRIS scores and computer-aided dynamic magnetic resonance imaging findings of hand and wrist as a measure of activity in rheumatoid arthritis |
| Q82037538 | Comparison of composite disease activity indices for rheumatoid arthritis |
| Q36171802 | Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort |
| Q35636621 | Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study |
| Q37703462 | Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis |
| Q92578081 | Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma |
| Q33668001 | Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies |
| Q40606444 | Concordance of Patient-Reported Joint Symptoms, Physician-Examined Arthritic Signs, and Ultrasound-Detected Synovitis in Rheumatoid Arthritis |
| Q39061281 | Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best? |
| Q55079883 | Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. |
| Q39066165 | Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. |
| Q41219509 | Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut-off points in |
| Q38013786 | Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model |
| Q61812081 | Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time |
| Q35470652 | Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. |
| Q36996859 | Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review |
| Q24812386 | DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment |
| Q24812591 | DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis |
| Q31061167 | Data-driven desirability function to measure patients' disease progression in a longitudinal study |
| Q35637402 | Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials |
| Q35555286 | Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity |
| Q92737263 | Defining new clinically derived criteria for high disease activity in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study |
| Q43800702 | Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis F |
| Q37145264 | Depicting and comparing the time to normalize "erythrocyte sedimentation rate" following two combination therapies in rheumatoid arthritis patients: a randomized clinical trial |
| Q61861925 | Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations |
| Q37456293 | Development and First Validation of a Disease Activity Score for Gout |
| Q38838252 | Development and testing of candidate items for inclusion in a new rheumatoid arthritis stiffness patient-reported outcome measure |
| Q44525783 | Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis |
| Q37350936 | Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect |
| Q37709990 | Development of an activity disease score in patients with uveitis (UVEDAI). |
| Q39346197 | Development of the Rheumatoid Arthritis Symptom Questionnaire (RASQ): a patient reported outcome scale for measuring symptoms of rheumatoid arthritis. |
| Q35620317 | Diagnostic properties of metabolic perturbations in rheumatoid arthritis |
| Q94174923 | Diagnostic value of high-resolution B-mode and doppler sonography for imaging of hand and finger joints in rheumatoid arthritis |
| Q54518906 | Discordance between clinical and imaging criteria: assessment by magnetic resonance imaging of the foot of patients with rheumatoid arthritis. |
| Q50554784 | Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? |
| Q35954667 | Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis pat |
| Q57169507 | Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice |
| Q40471904 | Disease assessment indices: activity, damage and severity. |
| Q73568460 | Do synovial fluid acute phase proteins from patients with rheumatoid arthritis originate from serum? |
| Q47857826 | Does a genetic variant in FOXO3A predict a milder course of rheumatoid arthritis? |
| Q40597614 | Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment? |
| Q24198056 | Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity |
| Q24193435 | Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity |
| Q41918491 | Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies |
| Q40799823 | Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome |
| Q37144969 | Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. |
| Q36555104 | Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. |
| Q24803670 | Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis |
| Q43683228 | Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study |
| Q34290335 | Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. |
| Q33652800 | Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis |
| Q92615892 | Effects of Conventional and Biological Drugs Used for the Treatment of Rheumatoid Arthritis on the Quality of Life and Depression |
| Q82906930 | Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity |
| Q41534957 | Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis. |
| Q35547757 | Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis |
| Q35550664 | Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. |
| Q35554130 | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed |
| Q44124054 | Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells |
| Q92737334 | Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry |
| Q38988830 | Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease |
| Q36145793 | Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis |
| Q34071287 | Etanercept (Enbrel): update on therapeutic use |
| Q30566220 | Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience |
| Q47776925 | Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis |
| Q38937827 | Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor |
| Q35547900 | Fatigue in primary Sjögren's syndrome |
| Q38742207 | Foot health in patients with rheumatoid arthritis-a scoping review. |
| Q35060515 | Fostering autonomous motivation, physical activity and cardiorespiratory fitness in rheumatoid arthritis: protocol and rationale for a randomised control trial |
| Q33629614 | Functional disability associated with disease and quality-of-life parameters in Chinese patients with rheumatoid arthritis |
| Q34418036 | Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts |
| Q35247643 | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
| Q35686104 | Health-related quality of life and disease activity in rheumatoid arthritis |
| Q51938404 | Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. |
| Q43852506 | High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study |
| Q36171850 | High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone |
| Q28480869 | High-sensitivity cardiac troponin-I is elevated in patients with rheumatoid arthritis, independent of cardiovascular risk factors and inflammation |
| Q46767224 | Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis |
| Q46865512 | Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis |
| Q44016937 | Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis |
| Q37843179 | Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: an observational study |
| Q83163065 | Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis |
| Q35555981 | Increased C reactive protein in response to acute stress in patients with rheumatoid arthritis |
| Q24816817 | Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia |
| Q35605630 | Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis |
| Q43772892 | Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis |
| Q37427257 | Inflammatory arthritis: an overview for primary care physicians |
| Q35548424 | Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis |
| Q54455943 | Inhibition of JNK in synovium by treatment with golimumab in rheumatoid arthritis. |
| Q37627037 | Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells |
| Q37340305 | Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage |
| Q45286659 | Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. |
| Q33460596 | Inverse association between air pressure and rheumatoid arthritis synovitis. |
| Q41534964 | Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis |
| Q35554765 | Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? |
| Q44247481 | Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? |
| Q83229780 | Is the Alifax Test-1TH useful to determine the Disease Activity Score (DAS28) in rheumatoid arthritis patients? |
| Q79210929 | Is three selected parameters adequate to monitor rheumatoid arthritis? |
| Q84651003 | Lack of Association of C-C Chemokine Receptor 5 Δ32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity |
| Q44237627 | Leucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients |
| Q58762092 | Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis |
| Q35551481 | Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. |
| Q48447140 | Long-term effects of a nurse-led group and individual patient education programme for patients with chronic inflammatory polyarthritis - a randomised controlled trial |
| Q33914779 | Long-term efficacy of radon spa therapy in rheumatoid arthritis--a randomized, sham-controlled study and follow-up |
| Q40636485 | Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup |
| Q47935954 | Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings |
| Q45372861 | Lower lifetime prevalence of atopy in rheumatoid arthritis |
| Q35554101 | MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years |
| Q52840082 | MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. |
| Q35547914 | Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset |
| Q35838697 | Management of early inflammatory arthritis. The long-term outcome and justification for early treatment |
| Q35552183 | Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis |
| Q34269994 | Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index [...] |
| Q33234551 | Measuring disease activity for rheumatoid arthritis |
| Q39043284 | Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients |
| Q40471892 | Methodological and statistical approaches to criteria development in rheumatic diseases. |
| Q39379414 | Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale |
| Q35554398 | Miscarriage but not fecundity is associated with progression of joint destruction in rheumatoid arthritis |
| Q98830298 | Model-Based Meta-analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development |
| Q50964701 | Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. |
| Q48304448 | Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice |
| Q90588166 | Motion analysis of the wrist joints in Chinese rheumatoid arthritis patients: a cross-sectional study |
| Q74455267 | Nephrotic syndrome associated with anti-tumor necrosis factor alpha therapy in a patient with rheumatoid arthritis: comment on the article by Charles et al |
| Q57780174 | Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis |
| Q35549071 | No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset |
| Q61628116 | Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data |
| Q31049240 | One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome |
| Q46786771 | Optic neuritis with concurrent etanercept and isoniazid therapy. |
| Q84594225 | Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q41446441 | Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis |
| Q47190952 | Outcome of transition phase patients with juvenile idiopathic arthritis. |
| Q42513048 | Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis |
| Q34143404 | Paid work is associated with improved health-related quality of life in patients with rheumatoid arthritis |
| Q43445519 | Parapharyngeal abscess in a patient receiving etanercept |
| Q33579206 | Parasympathetic dysfunction in rheumatoid arthritis patients with ocular dryness |
| Q37065115 | Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? |
| Q36009078 | Patients' confidence in coping with arthritis after nurse-led education; a qualitative study |
| Q38863495 | Patterns of angiotensin converting enzyme insertion/deletion gene polymorphism among an Egyptian cohort of patients with rheumatoid arthritis |
| Q38671016 | Patterns of circulatory and peripheral blood mononuclear cytokines in rheumatoid arthritis |
| Q46743986 | Perceived functional disabilities among rheumatoid arthritis patients |
| Q33413162 | Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline |
| Q30821758 | Performance of Routine Assessment of Patient Index Data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories |
| Q31038425 | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors |
| Q48287493 | Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. |
| Q43656829 | Periodontal therapy in chronic periodontitis lowers gingival crevicular fluid interleukin-1beta and DAS28 in rheumatoid arthritis patients |
| Q92451152 | Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol |
| Q33916929 | Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis |
| Q44683597 | Polysymptomatic distress in patients with rheumatoid arthritis: understanding disproportionate response and its spectrum |
| Q34896529 | Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind? |
| Q30500520 | Power Doppler sonography in the assessment of synovial tissue of the knee joint in rheumatoid arthritis: a preliminary experience |
| Q40712273 | Practice variation in the management of pharyngitis: the importance of variability in patients' clinical characteristics and in physicians' responses to them |
| Q33730446 | Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis |
| Q72456792 | Prediction of radiographic damage in hands and feet in rheumatoid arthritis by clinical evaluation |
| Q35111187 | Predictive factors related to the efficacy of golimumab in patients with rheumatoid arthritis |
| Q35551556 | Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis |
| Q71918207 | Prognostic significance of complement alleles Bf and C4 in early rheumatoid arthritis |
| Q35579462 | Psoriatic arthritis assessment tools in clinical trials |
| Q44557662 | Psoriatic arthritis. Treatment outcome parameters |
| Q48014888 | Psychometric evaluation of the Rheumatoid Arthritis Symptom Questionnaire (RASQ) in an observational study. |
| Q36406749 | Psychometric properties of three single-item pain scales in patients with rheumatoid arthritis seen during routine clinical care: a comparative perspective on construct validity, reproducibility and internal responsiveness |
| Q33579327 | Purine enzyme activities in recent onset rheumatoid arthritis: are there differences between patients and healthy controls? |
| Q35551164 | Purine enzymes in patients with rheumatoid arthritis treated with methotrexate |
| Q33566641 | Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine. A pilot study |
| Q40833060 | Quality of life 3. Rheumatoid arthritis |
| Q40401339 | Quality of life and costs for different treatment strategies for rheumatoid arthritis |
| Q81198316 | Quality of life in Indian patients with rheumatoid arthritis |
| Q35198211 | Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care |
| Q35159896 | RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies |
| Q40377000 | ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany |
| Q47202397 | Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies |
| Q35759974 | Radiological damage in patients with rheumatoid arthritis on sustained remission |
| Q33565436 | Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification? |
| Q34976746 | Radionuclide imaging with human polyclonal immunoglobulin (Tc-HIG) and bone scan in patients with rheumatoid arthritis and serum-negative polyarthritis |
| Q35549462 | Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions |
| Q73573994 | Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis |
| Q59791952 | Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs |
| Q36485737 | Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis |
| Q34903101 | Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis |
| Q51082282 | Relation between bone mineral density and IL-17 serum levels in Serbian patients with early Rheumatoid arthritis. |
| Q51355190 | Relationship between CDT and disease activity in rheumatoid arthritis. |
| Q47933669 | Relationship between high-resolution computed tomography findings and the Stoke index in patients with rheumatoid arthritis |
| Q46486846 | Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis |
| Q84717427 | Relative importance of the functional abilities comprising Health Assessment Questionnaire Disability Index among rheumatoid arthritis patients |
| Q87858469 | Remission criteria and activity indices in psoriatic arthritis |
| Q37738105 | Remission in juvenile idiopathic arthritis: current facts |
| Q38541414 | Remission in rheumatoid arthritis: is it all the same? |
| Q35449556 | Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria |
| Q35555937 | Response criteria for rheumatoid arthritis in clinical practice: how useful are they? |
| Q44011924 | Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients |
| Q64330138 | Responsiveness of Single versus Composite Measures of Pain in Knee Osteoarthritis |
| Q43052844 | Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis |
| Q73521737 | Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity |
| Q37043713 | Rheumatoid arthritis--early diagnosis and disease management |
| Q44927864 | Rheumatoid arthritis: assessing disease activity and outcome |
| Q36091751 | Rheumatoid arthritis: previously untreated early disease |
| Q43220265 | Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis |
| Q36675413 | Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis |
| Q38062332 | Same-day or historical ESR for disease activity score measurement: does it matter? |
| Q35553042 | Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis |
| Q99609018 | Seasonal and Weather Effects on Rheumatoid Arthritis: Myth or Reality? |
| Q40606429 | Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States |
| Q90175550 | Self-reported painful joint count and assessor-reported tender joint count as instruments to assess pain in hand osteoarthritis |
| Q36067062 | Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. |
| Q38425628 | Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis |
| Q50996608 | Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis. |
| Q36194217 | Severity and Diurnal Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis. |
| Q42061798 | Short-term effects of antirheumatic drugs |
| Q35915958 | Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? |
| Q36706945 | Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients |
| Q45230346 | Sonographic measurements of low-echoic synovial area in the dorsal aspect of metatarsophalangeal joints in healthy subjects |
| Q54105644 | Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. |
| Q79080037 | Stress–vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis |
| Q58220963 | Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS |
| Q35097516 | Symptoms, the nature of fibromyalgia, and diagnostic and statistical manual 5 (DSM-5) defined mental illness in patients with rheumatoid arthritis and fibromyalgia |
| Q33240856 | Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis |
| Q43481756 | Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial |
| Q40736371 | Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial |
| Q45150201 | Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q43800679 | The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients |
| Q35480214 | The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity |
| Q42675446 | The Hawthorne Effect, Sponsored Trials, and the Overestimation of Treatment Effectiveness |
| Q36000249 | The challenging interplay between rheumatoid arthritis, ageing and comorbidities |
| Q88113267 | The controversy of using PGA to define remission in RA |
| Q39638950 | The correlations of socioeconomic status, disease activity, quality of life, and depression/anxiety in Chinese patients with rheumatoid arthritis |
| Q79366300 | The effect of infliximab on chemokines in patients with rheumatoid arthritis |
| Q37172521 | The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people |
| Q36206897 | The impact of endpoint measures in rheumatoid arthritis clinical trials |
| Q81256806 | The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study |
| Q26765275 | The macrophages in rheumatic diseases |
| Q74552419 | The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al |
| Q80537897 | The patient-based outcome of upper-extremity surgeries using the DASH questionnaire and the effect of disease activity of the patients with rheumatoid arthritis |
| Q42661052 | The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis |
| Q38128780 | The rheumatoid forefoot |
| Q55689191 | The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. |
| Q35933694 | The role of outcome measures in assessing change in the at-risk rheumatoid foot |
| Q37633537 | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists |
| Q34648998 | Three groups in the 28 joints for rheumatoid arthritis synovitis--analysis using more than 17,000 assessments in the KURAMA database |
| Q46988765 | Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. |
| Q43854069 | Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy |
| Q37682799 | Tocilizumab in the treatment of rheumatoid arthritis and beyond |
| Q36185264 | Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update |
| Q38204241 | Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety |
| Q36300479 | Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations |
| Q35550470 | Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis |
| Q36485495 | Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study) |
| Q37178957 | Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial |
| Q35169330 | Use of conservative and surgical foot care in an inception cohort of patients with rheumatoid arthritis |
| Q33470696 | Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial |
| Q51104549 | Using the Juvenile Arthritis Disease Activity Score based on erythrocyte sedimentation rate or C-reactive protein level: results from the Portuguese register. |
| Q36428250 | Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity |
| Q53067521 | Validation of disease activity indices using the 28 joint counts in systemic sclerosis. |
| Q58112107 | Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28 |
| Q63101754 | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e |
| Q46374758 | Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus |
| Q41510568 | Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis |
| Q92063403 | Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis |
| Q33567430 | Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis |
| Q71602344 | Value of 99mTc-IgG scintigraphy in the prediction of joint destruction in patients with rheumatoid arthritis of recent onset |
| Q51104726 | Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. |
| Q24673434 | When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? |
| Q40603508 | Which Factors Influence Self-Efficacy in Patients with Chronic Inflammatory Polyarthritis? |
| Q35551485 | Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). |
| Q50446052 | YKL-40 and cytokines - a New Diagnostic Constellation in Rheumatoid Arthritis? |
| Q84600236 | [How do we evaluate an inadequate response in a patient with rheumaoid arthritis in the clinical praxis P?] |
| Q52933639 | [Planning of orthopedic surgery for rheumatoid arthritis]. |
| Q42244593 | rs2841277 (PLD4) is associated with susceptibility and rs4672495 is associated with disease activity in rheumatoid arthritis. |
Search more.